Skip to Content
Global News Select

CureVac Reports Unfavorable Covid-19 Vaccine Study Results Amid High Levels of Variants

By Josh Beckerman


CureVac NV reported unfavorable results in the second interim analysis of Covid-19 vaccine candidate CVnCoV, noting an "unprecedented broad diversity" of virus variants.

CureVac shares were recently down 50% after hours to $47.20.

"In the unprecedented context of at least 13 variants circulating within the study population subset assessed at this interim analysis, CVnCoV demonstrated an interim vaccine efficacy of 47% against COVID-19 disease of any severity and did not meet prespecified statistical success criteria," CureVac said. The favorable safety profile of the vaccine was confirmed.

The HERALD study, conducted by CureVac in conjunction with Bayer, enrolled about 40,000 people in 10 countries in Latin America and Europe.

In total, 134 Covid-19 cases were assessed in the interim analysis, with 124 of these sequenced to identify the variant causing the infection. The outcome confirms that only one case was attributable to the original SARS-CoV-2 virus, CureVac said.

In March, CureVac said it planned to expand and further specify the protocols of its CVnCoV trials, saying, "Rapid distribution of new virus variants in the countries where the study is conducted supports the need for further analysis specification for the anticipated case-driven interim analysis."

CureVac and GlaxoSmithKline PLC in February announced a partnership to develop a vaccine for emerging variants.


Write to Josh Beckerman at


(END) Dow Jones Newswires

June 16, 2021 18:11 ET (22:11 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.